Back

Effects of the PAR-1 receptor antagonist vorapaxar on platelet activation and coagulation biomarkers in patients with stable coronary artery disease

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Innovative drug therapies Antiplatelet Drugs ESC Premium Access ESC Congress 2018

About the speaker

Photo
Mrs Renske Olie

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))

8 More presentations in this session

Presentation thumbnail
Six-month treatment with novel oral anticoagulants ameliorates cerebral blood flow, as evaluated with brain perfusion SPECT.
Doctor H. Takeuchi (Ogachi, JP)
Abstract Slides Video
Presentation thumbnail
TAFI level dynamics during long-term warfarin therapy as a predictor of recurrent bleedings in a target INR
Professor N. Vorobyeva (Moscow, RU)
Abstract Slides Video
Presentation thumbnail
Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations
Doctor M. Krempf (Nantes, FR)
Abstract
Presentation thumbnail
Evaluation of the pharmacokinetics and pharmacodynamics of subcutaneously administered dutogliptin for daily injection with granulocyte colony stimulating factor (G-CSF) for AMI
Mr D. Nix (Lexington Township, US)
Abstract Slides Video
Presentation thumbnail
Multiple ascending doses of recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results
Doctor M. Bonaca (Aurora, US)
Abstract Slides Video

Access the full session

Session thumbnail
Innovative drug therapies

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources